Review
doi: 10.1200/JCO.22.01848.
Epub 2022 Dec 12.
Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma
Affiliations
- PMID: 36508700
- DOI: 10.1200/JCO.22.01848
Item in Clipboard
Review
Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma
J Clin Oncol.
.
Abstract
Diffuse large B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma, comprises a heterogenous group of morphologically, genetically, and clinically distinct diseases. Several recent advances have affected the treatment landscape, which had been mostly stagnant for the past few decades. We will review the practice-changing studies in frontline (POLARIX), early relapse (ZUMA-7 and TRANSFORM), and multiple recurrent (ZUMA-1, JULIET, TRANSCEND, L-MIND, and LOTIS-2) stages and discuss how the treatment landscape may evolve with the emergence of bispecific antibodies.
Similar articles
-
Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma.Curr Hematol Malig Rep. 2018 Dec;13(6):534-542. doi: 10.1007/s11899-018-0482-6. Curr Hematol Malig Rep. 2018. PMID: 30362020 Review.
-
The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma.Clin Lymphoma Myeloma Leuk. 2022 Jun;22(6):362-372. doi: 10.1016/j.clml.2021.11.010. Epub 2021 Nov 20. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34922844 Review.
-
Treatment strategies for patients with diffuse large B-cell lymphoma.Cancer Treat Rev. 2022 Nov;110:102443. doi: 10.1016/j.ctrv.2022.102443. Epub 2022 Jul 31. Cancer Treat Rev. 2022. PMID: 35933930 Review.
-
New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma.J Oncol Pharm Pract. 2022 Dec;28(8):1848-1858. doi: 10.1177/10781552221096165. Epub 2022 Apr 26. J Oncol Pharm Pract. 2022. PMID: 35469489 Review.
-
[New drug approval: Lisocabtagene maraleucel for patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma or follicular lymphoma grade 3B after two or more lines of systemic treatment].Bull Cancer. 2022 Sep;109(9):879-880. doi: 10.1016/j.bulcan.2022.04.020. Epub 2022 Jun 15. Bull Cancer. 2022. PMID: 35717220 French. No abstract available.
Cited by
-
Predictors of Survival, Treatment Modalities, and Clinical Outcomes of Diffuse Large B-Cell Lymphoma in Patients Older Than 70 Years Still an Unmet Medical Need in 2024 Based on Real-World Evidence.Cancers (Basel). 2024 Apr 11;16(8):1459. doi: 10.3390/cancers16081459. Cancers (Basel). 2024. PMID: 38672542 Free PMC article.
-
Racial and ethnic disparities in outcomes of diffuse large B cell lymphoma in adolescent and young adults: a SEER database analysis.Ann Hematol. 2024 Dec;103(12):5539-5547. doi: 10.1007/s00277-024-06075-2. Epub 2024 Nov 4. Ann Hematol. 2024. PMID: 39495284
-
Population based registry study on large B-cell lymphoma mortality and morbidity in Finland.Acta Oncol. 2025 Feb 25;64:303-311. doi: 10.2340/1651-226X.2025.42539. Acta Oncol. 2025. PMID: 39996583 Free PMC article.
-
Molecular classification and construction of the risk signature for diffuse large B-cell lymphoma based on vitamin B6 metabolism.Discov Oncol. 2025 Jul 11;16(1):1314. doi: 10.1007/s12672-025-03122-w. Discov Oncol. 2025. PMID: 40646302 Free PMC article.
-
Sophora flavescens-derived extracellular vesicles loaded with oncolytic vaccinia virus/IR1061 for NIR-II photoacoustic imaging guided multimodal treatment of diffuse large B-cell lymphoma.Mater Today Bio. 2025 Aug 6;34:102177. doi: 10.1016/j.mtbio.2025.102177. eCollection 2025 Oct. Mater Today Bio. 2025. PMID: 40822926 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous
